Alzheimer's disease is expected to rely on blood test February 06, 2018 Source: Science and Technology Daily The British journal Nature recently reported a recent study: beta-amyloid deposits in the brain are the earliest pathological features of Alzheimer's disease, and scientists have finally discovered predictable plasma biomarkers. And is expected to be widely used in clinical, early warning of the occurrence of Alzheimer's disease. Humans have so far failed to do anything about Alzheimer's disease. At present, β-amyloid levels in the brain can only be accurately assessed by PET imaging (positron emission tomography) or by measuring β-amyloid levels in cerebrospinal fluid. The medical community urgently needs a more economical low intrusion. Diagnostic tool. By combining immunoprecipitation and mass spectrometry, the National Research Center for Geriatrics and Geriatrics of Japan measured the levels of multiple β-amyloid-related peptides in the blood. They tested their methods with two separate datasets—one with a sample of 121 samples from Japan and one with 252 samples from Australia. Samples from both datasets were from humans and included both cognitively normal individuals, individuals with mild cognitive impairment, and Alzheimer's disease patients. Studies have shown that by comparing the ratio of different β-amyloid-related peptides and a comprehensive “scoreâ€, it is possible to accurately predict the level of β-amyloid deposition in an individual's brain. These plasma biomarkers are less invasive, more economical, and more expandable than current technologies and are expected to be widely used in the clinic. Currently, clinical trials that improve the progression of Alzheimer's disease are generally most effective for patients at the earliest stages of the disease, and these biomarkers can help doctors determine the most appropriate clinical trial participants, so they can be used to identify patients in the future. A high-risk individual with Alzheimer's disease. The research team also suggested that the effectiveness of this outcome as a disease monitoring tool still needs further evaluation, especially before it is widely used in clinical practice, and more effective research should be carried out. (Reporter Zhang Mengran) Insulin Syringes Needle,Disable Syringe,Monoject Syringe,10 Ml Syringe FOSHAN PHARMA CO., LTD. , https://www.fspharmamedicine.com